Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 12/20 | 0.62 |
| ▸ | LTB4R2 | Q9NPC1 | 8/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.62 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1322442 | 1.00 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6PTGDR2 | |
| SCHEMBL27898249 | 1.00 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6PTGDR2 | |
| SCHEMBL29846453 | 1.00 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6PTGDR2 | |
| Valsartan SCHEMBL2542 | 0.91 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21408288 | 0.91 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL157179 | 0.91 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL1560689 | 0.91 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL2329 | 0.91 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL29406387 | 0.91 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL2328 | 0.91 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0724387-A4 | TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES BY ANGIOTENSION II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1997-06-18 | — | — | EP | claimed |
| EP-0724387-A1 | TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES BY ANGIOTENSION II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-07 | — | — | EP | claimed |
| WO-1995006410-A1 | TREATMENT OF CHRONIC INFLAMMATORY DISEASES BY ANGIOTENSION II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-09 | — | — | WO | claimed |
| US-20220257551-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2022-08-18 | — | — | US | disclosed |
| US-20220133694-A1 | PHARMACEUTICAL USE | NOVARTIS PHARMACEUTICALS CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-20180344679-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-8796331-B2 | Methods of treatment and pharmaceutical composition | NOVARTIS AG (CH) | 2014-08-05 | — | — | US | disclosed |
| US-20130158086-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| US-20130158085-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| US-8404744-B2 | Methods of treatment and pharmaceutical composition | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20050101652-A1 | New salt hydrates | NOVARTIS PHARMACEUTICALS CORPORATION | 2005-05-12 | — | — | US | disclosed |
| EP-1505965-A1 | USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION | Novartis AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-20050004194-A1 | Use of organic compounds | GRAVES KURT CHUM (CH) | 2005-01-06 | — | — | US | disclosed |
| EP-1467728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS | Novartis AG (CH) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004054575-A1 | COMBINATIONS OF VALSARTAN WITH COX-2 INHIBITORS | NOVARTIS AG (CH) | 2004-07-01 | — | — | WO | disclosed |
| WO-2003094915-A1 | USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION | NOVARTIS AG (CH) | 2003-11-20 | — | — | WO | disclosed |
| US-20030144215-A1 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | NOVARTIS PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | disclosed |
| WO-2003059345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS | NOVARTIS AG (CH) | 2003-07-24 | — | — | WO | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133694-A1 | PHARMACEUTICAL USE | TNNT2, TNNI3, NPPA | AGTR1 1236/4885LTB4R2 1417/4885ABCB11 14/4885 |
| US-20030144215-A1 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | MME, REN, AGTR1 | AGTR1 3/4885LTB4R2 1816/4885ABCB11 1792/4885 |
| US-20050101652-A1 | New salt hydrates | REN, ACE, AGT | AGTR1 8/4885LTB4R2 4208/4885ABCB11 422/4885 |
| US-20130158086-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, AGTR1, TTR | AGTR1 2/4885LTB4R2 2125/4885ABCB11 713/4885 |
| US-20050004194-A1 | Use of organic compounds | ACE, ACE2, AGT | AGTR1 4/4885LTB4R2 869/4885ABCB11 1237/4885 |
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, MME, ACE | AGTR1 4/4885LTB4R2 1382/4885ABCB11 151/4885 |
| US-20220257551-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | MME, DNPEP, AGTR1 | AGTR1 3/4885LTB4R2 2298/4885ABCB11 2470/4885 |
| US-20130158085-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, AGTR1, TTR | AGTR1 2/4885LTB4R2 2125/4885ABCB11 713/4885 |
| US-20180344679-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | REN, MME, AGTR1 | AGTR1 3/4885LTB4R2 767/4885ABCB11 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.